Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin

Brad Clark, Sarah M. Woolford, Annette Eastwood, Ken Sharpe, Peter G. Barnes, Christopher J Gore

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.

    Original languageEnglish
    Pages (from-to)1561-1571
    Number of pages11
    JournalDrug Testing and Analysis
    Volume9
    Issue number10
    DOIs
    Publication statusPublished - Oct 2017

    Fingerprint

    hematology
    Physiology
    Hematology
    Erythropoietin
    physiology
    Athletes
    Doping (additives)
    Physiological Adaptation
    dose
    hemoglobin
    bycatch
    Exercise Test
    Sports
    Hemoglobins
    Blood
    blood
    Placebos
    Control Groups

    Cite this

    Clark, Brad ; Woolford, Sarah M. ; Eastwood, Annette ; Sharpe, Ken ; Barnes, Peter G. ; Gore, Christopher J. / Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin. In: Drug Testing and Analysis. 2017 ; Vol. 9, No. 10. pp. 1561-1571.
    @article{7b200c251c20413383e0e5f1d68d99a1,
    title = "Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin",
    abstract = "There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.",
    keywords = "ABP, Doping, EPO, Micro-dosing, Performance",
    author = "Brad Clark and Woolford, {Sarah M.} and Annette Eastwood and Ken Sharpe and Barnes, {Peter G.} and Gore, {Christopher J}",
    year = "2017",
    month = "10",
    doi = "10.1002/dta.2176",
    language = "English",
    volume = "9",
    pages = "1561--1571",
    journal = "Drug Testing and Analysis",
    issn = "1942-7603",
    publisher = "John Wiley & Sons",
    number = "10",

    }

    Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin. / Clark, Brad; Woolford, Sarah M.; Eastwood, Annette; Sharpe, Ken; Barnes, Peter G.; Gore, Christopher J.

    In: Drug Testing and Analysis, Vol. 9, No. 10, 10.2017, p. 1561-1571.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin

    AU - Clark, Brad

    AU - Woolford, Sarah M.

    AU - Eastwood, Annette

    AU - Sharpe, Ken

    AU - Barnes, Peter G.

    AU - Gore, Christopher J

    PY - 2017/10

    Y1 - 2017/10

    N2 - There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.

    AB - There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.

    KW - ABP

    KW - Doping

    KW - EPO

    KW - Micro-dosing

    KW - Performance

    UR - http://www.scopus.com/inward/record.url?scp=85017437045&partnerID=8YFLogxK

    U2 - 10.1002/dta.2176

    DO - 10.1002/dta.2176

    M3 - Article

    VL - 9

    SP - 1561

    EP - 1571

    JO - Drug Testing and Analysis

    JF - Drug Testing and Analysis

    SN - 1942-7603

    IS - 10

    ER -